Introduction {#S0001}
============

Numerous studies have demonstrated that statins reduce the incidence of coronary events in patients at high risk for coronary events \[[@CIT0001]--[@CIT0008]\]. The efficacy of statins in reducing coronary events in an outpatient cardiology practice needed to be investigated. This article reports data comparing the incidence of new myocardial infarction (MI), of new percutaneous coronary intervention (PCI), and of new coronary artery bypass graft surgery (CABGs) in 305 patients, mean age 74 years (93% with coronary artery disease), treated in an academic community cardiology practice during the time they were not treated with statins vs. during the time they were subsequently treated with statins.

Material and methods {#S0002}
====================

Paper and electronics chart reviews were used to screen patients treated with statins at an academic community cardiology practice from 1978 to 2008. Based on the starting date of statin use, long-term clinical outcomes before and after statins start dates were calculated and compared. Patients who were treated with statins within the first year of follow-up were excluded from the study in order to achieve comparable duration of follow-up. Out of 1, 599 patients screened at the practice \[[@CIT0009]\], 305 patients met all criteria and were included in the study.

For every patient, progress notes of all interim visits, letters of correspondence, medication use, blood pressure, laboratory studies including serum lipid levels, and occurrence of adverse cardiovascular events from the time of initial presentation to the last follow-up were recorded. Adverse events included occurrence of MI, need for PCI, and need for CABGs. Drug therapy and patient comorbidities including coronary artery disease, hyperlipidemia, hypertension, diabetes mellitus, cigarette smoking history, congestive heart failure, angina, atrial fibrillation, chronic kidney disease, peripheral arterial disease, abdominal aortic aneurysm, carotid artery stenosis, transient ischemic attack, stroke, and previous MI, PCI, and CABGS were recorded. Dates of the events as well as dates of medication initiation and discontinuation were recorded. Coronary artery disease was diagnosed as previously described \[[@CIT0010]--[@CIT0016]\].

Data were extracted by the physician authors and tabulated with Microsoft Access 2003 (Microsoft Corporation, Redmond, WA, USA). Customized computer programming was written for macros within Microsoft Excel 2003. The McNemar test was used to compare clinical outcomes. Adverse events occurring before the time of initial presentation were not included in the outcomes analysis. Stepwise logistic regression was performed with MEDCAL statistical software using the 48 variables listed in [Tables I](#T0001){ref-type="table"} and [II](#T0002){ref-type="table"} to determine if use of statins was independently associated with MI, PCI, and CABGS. A two-sided *p* value of \< 0.05 was considered significant.

###### 

Baseline characteristics of 305 patients

  ------------------------------------------------ -----------
  **Age \[years\]**                                74 ±10
  **Men**                                          217
  **Women**                                        88
  **Follow-up before statin use \[months\]**       65
  **Follow-up after statin use \[months\]**        64
  **Coronary artery disease**                      283 (93%)
  **Hyperlipidemia**                               270 (89%)
  **Hypertension**                                 251 (82%)
  **Diabetes mellitus**                            76 (25%)
  **Congestive heart failure**                     49 (16%)
  **Angina pectoris**                              35 (11%)
  **Atrial fibrillation**                          54 (18%)
  **Carotid artery stenosis**                      18 (6%)
  **Stroke**                                       30 (10%)
  **Transient ischemic attack**                    18 (6%)
  **Chronic renal disease**                        8 (3%)
  **Peripheral arterial disease**                  35 (11%)
  **Abdominal aortic aneurysm**                    12 (4%)
  **Smoker**                                       130 (43%)
  **Prior myocardial infarction**                  102 (33%)
  **Prior percutaneous coronary intervention**     49 (16%)
  **Prior coronary artery bypass graft surgery**   49 (16%)
  ------------------------------------------------ -----------

###### 

Drug therapy in 305 patients

  Medications                                Number (%)   Mean duration
  ------------------------------------------ ------------ ---------------
  Statins                                    305 (100)    5.36
  Ezetimibe                                  78 (26)      2.12
  Niacin                                     26 (9)       2.49
  Bile acid sequestrants                     7 (2)        1.12
  Fibrates                                   34 (11)      3.42
  Fish oils                                  14 (5)       1.94
  β-Blockers                                 260 (85)     8.06
  Diuretics                                  180 (59)     5.72
  Angiotensin-converting enzyme inhibitors   225 (74)     5.38
  Angiotensin receptor blockers              102 (33)     3.76
  Calcium channel blockers                   187 (61)     6.29
  Other antihypertensives                    32 (10)      4.73
  Aspirin                                    270 (89)     8.41
  Ticlopidine                                10 (3)       3.18
  Clopidogrel                                82 (27)      2.19
  Aspirin/extended-release dipyridamole      2 (1)        3.34
  Other antiplatelet drugs                   6 (2)        2.90
  Warfarin                                   100 (33)     4.90
  Nitrates                                   116 (38)     5.26
  Digoxin                                    70 (23)      5.34
  Cilostazol                                 3 (1)        2.65
  Insulin                                    24 (8)       8.60
  Thiazolidinediones                         35 (11)      3.08
  Sulfonylureas                              47 (15)      5.37
  Metformin                                  38 (12)      4.55
  Sitagliptin                                2 (1)        0.64

Results {#S0003}
=======

[Table I](#T0001){ref-type="table"} shows the baseline characteristics of the 305 patients. [Table II](#T0002){ref-type="table"} shows the prevalence of use of drugs in the 305 patients before, after, and before and after use of statins. [Table III](#T0003){ref-type="table"} shows the mean blood pressure and serum lipids levels before and after use of statins. [Table III](#T0003){ref-type="table"} also shows levels of statistical significance. [Table IV](#T0004){ref-type="table"} shows the incidence of MI, of PCI, and of CABGs before and after treatment with statins. [Table III](#T0003){ref-type="table"} also shows levels of statistical significance.

###### 

Blood pressure and serum lipid levels before and after statin therapy

  Variable                            Before statins   After statins   Value of *p*
  ----------------------------------- ---------------- --------------- --------------
  Systolic blood pressure \[mmHg\]    134 ±14          130 ±13         \< 0.01
  Diastolic blood pressure \[mmHg\]   78 ±8            73 ±7           \< 0.001
  Mean arterial pressure \[mmHg\]     97 ±9            92 ±8           \< 0.001
  Total cholesterol                   195 ±43          157 ±32         \< 0.001
  LDL cholesterol \[mg/dl\]           118 ±38          80 ±22          \< 0.001
  HDL cholesterol \[mg/dl\]           45 ±13           49 ±15          \< 0.01
  Triglycerides \[mg/dl\]             168 ±96          147 ±82         \< 0.05

LDL -- low-density lipoprotein, HDL -- high-density lipoprotein

###### 

Incidence of myocardial infarction and coronary revascularization before and after use of statins

                                            Before statins   After statins   Value of *p*
  ----------------------------------------- ---------------- --------------- --------------
  **Myocardial infarction**                 31 (10%)         13 (4%)         \< 0.01
  **Percutaneous coronaryintervention**     66 (22%)         41 (13%)        \< 0.01
  **Coronary artery bypassgraft surgery**   56 (18%)         20 (7%)         \< 0.001

Stepwise logistic regression analysis showed that use of statins was a significant independent predictor of new MI (odds ratio = 0.0207; 95% CI 0.0082-0.0522; *p* \< 0.0001), of new PCI (odds ratio = 0.0109; 95% CI 0.0038-0.0315; *p* \< 0.0001) and of new CABGs (odds ratio = 0.0177; 95% CI 0.0072-0.0431; *p* \< 0.0001).

Discussion {#S0004}
==========

Numerous studies have demonstrated that statins reduce the incidence of coronary events in patients at high risk for coronary events \[[@CIT0001]--[@CIT0008]\]. The present study compared the incidence of new MI, of new PCI, and of new CABGs in 305 patients, mean age 74 years (93% with coronary artery disease), treated in an academic community cardiology practice during the time they were not treated with statins versus during the time they were subsequently treated with statins.

At 65-month follow-up before treatment with statins and at 64-month follow-up after treatment with statins, the incidence of new MI was significantly reduced from 10% to 4% by statins (*p* \< 0.01), the incidence of new PCI was significantly reduced from 22% to 13% by statins (*p* \< 0.01), and the incidence of new CABGs was significantly reduced from 18% to 7% by statins (*p* \< 0.001). Stepwise logistic regression analysis using 48 variables showed that use of statins was a significant independent risk factor for reducing new MI, new PCI and new CABGs (*p* \< 0.0001).

Our data show that use of statins in patients with overt coronary artery disease (93%) or at high-risk for coronary artery disease in a community cardiology practice can reduce their chance of developing new MI, new PCI and new CABGs. This study should give community practitioners, both specialists and primary care providers, the encouragement to pursue cardiovascular risk reduction strategies as a means for reducing new MI, PCI and CABGs in their patients.

A limitation of this study is that it is a retrospective chart analysis study with all inherent problems of such a design.
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